Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - beclometasone dipropionate, quantity: 0.05 mg/actuation - inhalation, pressurised - excipient ingredients: ethanol; norflurane - for the prophylactic management of asthma.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - beclometasone dipropionate, quantity: 0.05 mg/actuation - inhalation, pressurised - excipient ingredients: ethanol; norflurane - for the prophylactic management of asthma in adults. indications as at 19 july 2000: for the prophylactic management of asthma.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - phentermine, quantity: 15 mg - capsule, modified release - excipient ingredients: iron oxide yellow; magnesium stearate; liquid paraffin; brilliant blue fcf; lactose monohydrate; sodium polystyrene sulfonate; iron oxide black; titanium dioxide; gelatin; sodium lauryl sulfate; silicon dioxide - duromine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with duromine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2) which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - phentermine, quantity: 40 mg - capsule, modified release - excipient ingredients: lactose monohydrate; sunset yellow fcf; liquid paraffin; magnesium stearate; erythrosine; iron oxide black; titanium dioxide; sodium polystyrene sulfonate; gelatin; sodium lauryl sulfate; silicon dioxide - duromine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with duromine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2) which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals australia pty ltd - phenoxymethylpenicillin -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - dihydrocodeine tartrate, quantity: 1.9 mg/ml - oral liquid - excipient ingredients: purified water; sucrose; citric acid; methyl hydroxybenzoate; amaranth; sorbitol; flavour - for relief of stubborn, unproductive cough.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals australia pty ltd - flucytosine -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - imiquimod, quantity: 50 mg/g - cream - excipient ingredients: benzyl alcohol; glycerol; white soft paraffin; stearyl alcohol; isostearic acid; sorbitan monostearate; propyl hydroxybenzoate; xanthan gum; polysorbate 60; purified water; methyl hydroxybenzoate; cetyl alcohol - aldara 5% cream is indicated for treatment of solar (actinic) keratosis on the face and the scalp (see precautions), and primary treatment of confirmed superficial basal cell carcinoma where surgery is considered inappropriate, and the treatment of external genital and peri-anal warts (condyloma acuminata) in adults (see precautions).

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - imiquimod, quantity: 50 mg/g - cream - excipient ingredients: methyl hydroxybenzoate; cetyl alcohol; xanthan gum; propyl hydroxybenzoate; polysorbate 60; isostearic acid; glycerol; white soft paraffin; benzyl alcohol; stearyl alcohol; purified water; sorbitan monostearate - aldara 5% cream is indicated for treatment of solar (actinic) keratosis on the face and the scalp (see precautions), and primary treatment of confirmed superficial basal cell carcinoma where surgery is considered inappropriate, and the treatment of external genital and peri-anal warts (condyloma acuminata) in adults (see precautions).

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - flecainide acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; hydrogenated vegetable oil; magnesium stearate; croscarmellose sodium; pregelatinised maize starch - supraventricular arrhythmias: (a) due to pre-excitation syndromes, eg wolff-parkinson-white and lown-ganong-levine syndromes. (b) due to dual av nodal pathways in patients with debilitating symptoms. (c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. although tambocor may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, tambocor should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate. use of tambocor in chronic atrial fibrillation has not been adequately studied and is not recommended. 2. life threatening ventricular arrhythmias not controlled by other drugs. intravenous tambocor is indicated when rapid control or short-term prophylaxis of the above arrhythmias is the main clinical requir